CCI15106

CCI15106 is an investigational inhaled drug developed by GSK for the treatment of respiratory diseases, specifically targeting moderate chronic obstructive pulmonary disease (COPD). It was formulated as a dry powder for inhalation and evaluated in early-phase clinical trials to assess its safety, tolerability, pharmacokinetics, and environmental exposure in both healthy volunteers and patients with COPD. The studies included single and repeat escalating doses. While the precise mechanism of action is not explicitly stated in public sources, patent literature suggests that it may act as a Janus kinase (JAK) inhibitor—a class known to modulate cytokine signaling involved in inflammatory processes within the lungs. Development of CCI15106 has been discontinued after Phase 1 trials.

Other names

inhaled ribavirinribavirin-PRINT-CFIribavirin-PRINT-IP